Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).
Publication/Presentation Date
2-2018
Published In/Presented At
Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).. JCO 36, 614-614(2018).
DOI:10.1200/JCO.2018.36.4_suppl.614Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute
Document Type
Article
COinS